Research & Development
Delfi Diagnostics to present proof-of-concept data for liver cancer detection platform
Delfi Diagnostics will present data on the efficacy of their liver cancer detection platform at the American Association for the Study of Liver Disease annual meeting.
October 28, 2022
Bionano Genomics announces study of optical genome mapping for hepatocellular carcinoma
The study combined optical genome mapping with whole genome sequencing to maximize the detection of pathogenic variants.
October 4, 2022
Helio publishes study of HelioLiver cancer test
In a prospective phase II study, HelioLiver demonstrated high specificity (91%) and high sensitivity (76%) in detecting early-stage (stage I and II) HCC. In addition, it significantly outperformed other clinically available detection tools such as serum alpha-fetoprotein (AFP) (57%), GALAD (gender, age, Lens culinaris agglutinin-reactive AFP, and des-gamma-carboxy prothrombin [DCP]) scores (65%), and ultrasound (47%) (Hepatology Communications, March 3, 2022).
March 9, 2022
Fujifilm Medical to add IVD to portfolio
Fujifilm Wako Diagnostics has developed biomarkers that assess the risk of hepatocellular carcinoma in patients with chronic liver disease, as well as IVD reagents for disorders of lipid metabolism, lupus, rheumatoid arthritis, coronary heart disease, and diabetes, according to Fujifilm Medical Systems.
August 16, 2020
Liver cancer diagnostic test offers promise of early detection
The platform is called EV Click Chips, and the hope is that it will enable more effective purification of extracellular vesicles in blood from people with hepatocellular carcinoma. Researchers from the University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center have received a $2.97 million grant from the U.S. National Cancer Institute (NCI) to develop the technology further.
August 4, 2020
Google reports pathology AI helps predict survival in cancer patients
The deep-learning system was developed and tested using histopathology slides for patients with 10 cancer types -- including bladder cancer, invasive breast cancer, and head and neck squamous cell carcinoma -- drawing from publicly available data from the Cancer Genome Atlas (TCGA) program.
June 17, 2020
Genetic causes identified for three rare diseases
Researchers in study validate test to identify newborns with homocystinuria, a rare inherited disease
FDA reissues EUA for Janssen COVID-19 vaccine, includes warning about risks of myocarditis, pericarditis
Duke University researchers discover biomarkers may identify early pancreatic cancer risk
Netherlands researchers combine CRISPR, bioluminescence in proof-of-concept infectious disease test
Werfen completes $2B acquisition of Immucor, expands presence in specialized diagnostics
Blood test identifies patients at risk for liver cancer
The test analyzes patients' previous viral exposure to accurately predict whether they might develop hepatocellular carcinoma (HCC). It was created by researchers from the U.S. National Institutes of Health and several academic centers to help improve liver cancer screening and early detection.
June 11, 2020
Study calls for hepatitis D screening in at-risk patients
A review of the literature suggests that those who have hepatitis D along with hepatitis B have up to three times the risk for developing hepatocellular carcinoma than if they had hepatitis B alone, reported researchers at the University of Geneva and Geneva University Hospitals, in an article in press. This assessment was based on an analysis of data from 93 studies including a total of more than 100,000 patients.
May 19, 2020
Page 1 of 1